Pharmaceutical Express: The application for the market launch of the new drug Tengotinib tablets has been accepted by the National Medical Products Administration.

Yaojieankang-B announcement, the new drug application for Tengotinib tablets has been accepted by the China National Medical Products Administration Drug Evaluation Center, intended for the treatment of advanced, metastatic, or unresectable bile duct cancer in adult patients who have received at least one prior systemic treatment and FGFR inhibitor treatment. Previously, the indication of Tengotinib tablets has been approved to be included in the priority review list and breakthrough therapy list.